A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines.
Sixteen EU scientists and doctors were interviewed about pandemic planning using psychometric methods applied to a scientific problem for the first time. Criticism was aimed at countries which have no plan whatsoever, the majority of nations. Many such countries have not invested in scientific infrastructure and public health. Amongst the 15 or so published pandemic plans a lack of detail was identified. Of particular need was investment into avian virus vaccine stocks (H1-15), prepared licenses of vaccine and pre purchase and agreed distribution, investment into stocks of antivirals, antibiotics and masks. Most but not all members of the group predicted a global outbreak within 5 years, most probably starting in SE Asia. However it was recognised that a pandemic could start anywhere in the world which had juxtaposition of young people, chickens, ducks and pigs. Mammalian cell culture production using wild type virus with the production factory at category III levels of security was exemplified. Antivirals would be essential to ameliorate the first wave of infection although significant quantities of cell grown vaccine could be produced if, as in 1918, 1957 and 1968 there is a long period between the first virus isolation and person to person spread. The wider scientific community is more energised than previously for very serious preparations to be in place way before the outbreak begins as this is a major public health problem, completely dwarfing concerns about bioterrorism.
Oxford
J S
JS
Centre for Infectious Diseases, Retroscreen Virology Ltd, Bart's and The London, Queen Mary's School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS, UK. j.s.oxford@retroscreen.com
Manuguerra
C
C
Kistner
O
O
Linde
A
A
Kunze
M
M
Lange
W
W
Schweiger
B
B
Spala
G
G
Rebelo de Andrade
H
H
Pérez Breña
P R
PR
Beytout
J
J
Brydak
L
L
Caraffa de Stefano
D
D
Hungnes
O
O
Kyncl
J
J
Montomoli
E
E
Gil de Miguel
A
A
Vranckx
R
R
Osterhaus
A
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D018929:Cell Culture Techniques; D003625:Data Collection; D004189:Disaster Planning; D004196:Disease Outbreaks; D004363:Drug Utilization; D005060:Europe / Q000453:epidemiology; D005062:European Union; D006291:Health Policy; D006801:Humans; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000453:epidemiology* / Q000517:prevention & control / Q000628:therapy; D008322:Mammals; D009975:Orthomyxoviridae / Q000276:immunology
D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D007252:Influenza Vaccines